Normalization of low-density lipoprotein receptor expression in receptor defective homozygous familial hypercholesterolemia by inhibition of PCSK9 with alirocumab

Journal of the American College of Cardiology

Volumn 64, Issue 21, 2014, Pages 2299-2300

  Lambert, Gilles ^a   Chatelais, Mathias ^b   Petrides, Francine ^b   Passard, Maxime ^b   Thedrez, Aurélie ^b   Rye, Kerry Anne ^b   Schwahn, Uwe ^b   Gusarova, Viktoria ^b   Blom, Dirk J ^b   Sasiela, William ^b   Marais, A David ^b  

^a HÔTEL DIEU   (France)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALIROCUMAB; COMPACTIN; EVOLOCUMAB; LOW DENSITY LIPOPROTEIN RECEPTOR; MONOCLONAL ANTIBODY; PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9; SERINE PROTEINASE; UNCLASSIFIED DRUG;

CONCENTRATION RESPONSE; DRUG EFFICACY; DRUG MECHANISM; ENZYMATIC DEGRADATION; ENZYME INHIBITION; FAMILIAL HYPERCHOLESTEROLEMIA; FLOW CYTOMETRY; FLUORESCENCE ANALYSIS; GAIN OF FUNCTION MUTATION; HUMAN; LETTER; PROTEIN EXPRESSION; SKIN FIBROBLAST; UPREGULATION;

EID: 84961288617     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2014.07.995     Document Type: Letter

References (4)

1. E.A. Stein, and F. Raal Reduction of low-density lipoprotein cholesterol by monoclonal antibody inhibition of PCSK9 Annu Rev Med 65 2014 417 431
2. H.H. Hobbs, D.W. Russell, M.S. Brown, and J.L. Goldstein The LDL receptor locus in familial hypercholesterolemia: mutational analysis of a membrane protein Annu Rev Genet 24 1990 133 170
3. G. Lambert, F. Petrides, and M. Chatelais Elevated plasma PCSK9 is equally detrimental for non-familial hypercholesterolemic (non-FH) and heterozygous FH patients, irrespective of their LDL receptor defects J Am Coll Cardiol 63 2014 2365 2373
4. E.A. Stein, N. Honarpour, and S.M. Wasserman Effect of the proprotein convertase subtilisin/kexin 9 monoclonal antibody, AMG 145, in homozygous familial hypercholesterolemia Circulation 128 2013 2113 2120